ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Presentations

Investors & Media

  • Home
  • Investors & Media
  • Presentations
Investors & Media

Investors & Media

  • Overview
  • News / Events
  • Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Corporate Presentations

Corporate Presentation
Corporate Presentation

Published: November 16, 2020

2019 R&D Day Presentation
2019 R&D Day Presentation

Published: May 14, 2019

Audio Replay

Other Presentations

Exebacase Reduced Length of Stay and 30-Day Readmission Rates for US Patients with MRSA Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics Alone in a Phase 2 Study
Exebacase Reduced Length of Stay and 30-Day Readmission Rates for US Patients with MRSA Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics Alone in a Phase 2 Study

Published: October 3, 2019

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase(CF-301) in Pre-Clinical Models<br>ASM 2019, Outstanding Abstract Award
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase(CF-301) in Pre-Clinical Models
ASM 2019, Outstanding Abstract Award

Published: June 22, 2019

Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics (SOC) Alone In A First-in-Patient Phase 2 Study
Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics (SOC) Alone In A First-in-Patient Phase 2 Study

Published: April 16, 2019

Direct Lytic Agents: differentiated, first-in-class biologics for the treatment of life-threatening and drug-resistant infections
Direct Lytic Agents: differentiated, first-in-class biologics for the treatment of life-threatening and drug-resistant infections

Published: April 14, 2019

Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against <em>Pseudomonas aeruginosa</em>
Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against Pseudomonas aeruginosa

Published: February 26, 2019

Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis
Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis

Published: November 6, 2018

© 2021 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter